AR013477A1 - Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. - Google Patents
Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.Info
- Publication number
- AR013477A1 AR013477A1 ARP980104479A ARP980104479A AR013477A1 AR 013477 A1 AR013477 A1 AR 013477A1 AR P980104479 A ARP980104479 A AR P980104479A AR P980104479 A ARP980104479 A AR P980104479A AR 013477 A1 AR013477 A1 AR 013477A1
- Authority
- AR
- Argentina
- Prior art keywords
- useful
- compounds
- prostaglandinas
- aromatico
- tetrahidro
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000020084 Bone disease Diseases 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Analogos de PGH. En particular, se selecciona con compuestos que tienen una estructura de acuerdo con la siguiente formula I donde R1, R2, R3, R4, X, Y y Zson como se los define. Esta invencion también incluye isomeros opticos, diaesteromerosy enantiomeros de la formula anteriormente descripta, y salesaceptables desde el punto de vista farmacéutico, amidas biohidrolizables, ésteres y sus imidas. Los compuestos de la presente invencion son utiles parael tratamiento de una variedad de enfermedades y trastornos, como el glaucoma y los trastornos oseos. En consecuencia, la invencion también proveecomposiciones farmacéuticas que comprenden estas composiciones. La invencion proporciona además métodos de tratamiento para el glaucoma y los trastornososeos mediante el uso de estos compuestos o las composiciones que los contienen
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5821797P | 1997-09-09 | 1997-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013477A1 true AR013477A1 (es) | 2000-12-27 |
Family
ID=22015427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104479A AR013477A1 (es) | 1997-09-09 | 1998-09-08 | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5977173A (es) |
| EP (1) | EP1012136B1 (es) |
| JP (1) | JP2001515882A (es) |
| KR (1) | KR20010023839A (es) |
| CN (1) | CN1269786A (es) |
| AR (1) | AR013477A1 (es) |
| AT (1) | ATE270660T1 (es) |
| AU (1) | AU731153B2 (es) |
| BR (1) | BR9811774A (es) |
| CA (1) | CA2303764C (es) |
| CO (1) | CO4970731A1 (es) |
| DE (1) | DE69824966T2 (es) |
| ES (1) | ES2223141T3 (es) |
| HU (1) | HUP0100638A3 (es) |
| ID (1) | ID23971A (es) |
| IL (1) | IL134839A0 (es) |
| NO (1) | NO20001141L (es) |
| NZ (1) | NZ503735A (es) |
| PE (1) | PE115499A1 (es) |
| PL (1) | PL339212A1 (es) |
| SK (1) | SK3372000A3 (es) |
| TR (1) | TR200000671T2 (es) |
| WO (1) | WO1999012895A1 (es) |
| ZA (1) | ZA988230B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01008955A (es) * | 1999-03-05 | 2002-04-24 | Procter & Gamble | Analogos de prostaglandinas selectivas de fp no saturadas de c16. |
| EP1202999B1 (en) * | 1999-08-04 | 2003-06-18 | The Procter & Gamble Company | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
| US6894175B1 (en) * | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| KR100437873B1 (ko) * | 2001-05-08 | 2004-06-26 | 연성정밀화학(주) | 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질 |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| EP1812017A2 (en) * | 2004-10-21 | 2007-08-01 | Duke University | Ophthamological drugs |
| US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US20100074857A1 (en) * | 2008-09-23 | 2010-03-25 | Pamela Lipkin | Compositions and methods to treat epithelial-related conditions |
| KR20100099145A (ko) * | 2007-10-31 | 2010-09-10 | 파멜라 립킨 | 프로스타글란딘 유사체 조성물 및 상피 관련 질환을 치료하는 방법 |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| JP2012507552A (ja) | 2008-10-29 | 2012-03-29 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | プロスタグラジンのアミノ酸塩 |
| US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| WO2010077101A2 (ko) | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| KR20170095402A (ko) | 2009-11-09 | 2017-08-22 | 알러간, 인코포레이티드 | 모발 성장을 촉진하기 위한 조성물 및 방법 |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
| PL3811943T3 (pl) | 2013-03-15 | 2023-06-12 | Aerie Pharmaceuticals, Inc. | Związek do stosowania w leczeniu zaburzeń oczu |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
| JP2020515583A (ja) | 2017-03-31 | 2020-05-28 | アエリエ ファーマシューティカルズ インコーポレイテッド | アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 |
| CA3112391A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776938A (en) * | 1958-05-28 | 1973-12-04 | S Bergstrom | Dihydro-pge1 |
| US4011262A (en) * | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
| US4024179A (en) * | 1972-11-08 | 1977-05-17 | Pfizer Inc. | Substituted ω-pentanorprostaglandins |
| IL43571A (en) * | 1972-11-08 | 1977-08-31 | Pfizer | Omega-pentanorprostaglandins and their preparation |
| JPS5720305B2 (es) * | 1973-02-28 | 1982-04-27 | ||
| DE2365101A1 (de) * | 1973-12-21 | 1975-07-10 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
| DE2460990A1 (de) * | 1974-12-21 | 1976-07-01 | Hoechst Ag | Neue prostaglandin-analoga und verfahren zu ihrer herstellung |
| GB1507211A (en) * | 1975-02-14 | 1978-04-12 | Ono Pharmaceutical Co | Prostaglandin analogues |
| GB1506816A (en) * | 1975-03-31 | 1978-04-12 | Upjohn Co | Prostaglandins |
| DE2517771A1 (de) * | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
| US4051238A (en) * | 1976-06-03 | 1977-09-27 | The Upjohn Company | Treatment of genital tract diseases of domestic animals with prostaglandins |
| DE2737808A1 (de) * | 1976-08-27 | 1978-03-16 | Pfizer | 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine |
| US4206151A (en) * | 1978-12-21 | 1980-06-03 | American Cyanamid Company | 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series |
| US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
| US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| ES2213504T1 (es) * | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| CA2030345C (en) * | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
| CA2039420C (en) * | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| US5302617A (en) * | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| DE4024347A1 (de) * | 1990-07-27 | 1992-01-30 | Schering Ag | Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5332730A (en) * | 1992-10-16 | 1994-07-26 | Allergan, Inc. | Azido derivatives of cyclopentane heptanoic or heptenoic acid |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5545665A (en) * | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US6169111B1 (en) * | 1995-06-07 | 2001-01-02 | Alcon Laboratories, Inc. | Conformationally rigid aryl prostaglandins for use in glaucoma therapy |
| AU7680096A (en) * | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
| DE69714698T2 (de) * | 1996-06-10 | 2002-12-05 | Sucampo Ag | Endothelin-antagonisten |
| WO1998012175A1 (fr) * | 1996-09-17 | 1998-03-26 | Asahi Glass Company Ltd. | Derives de prostaglandine fluores et medicaments |
| AU5258698A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
| AU5436198A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
| US6037368A (en) * | 1997-05-09 | 2000-03-14 | Mount Sinai School Of Medicine | 8-iso- prostaglandins for glaucoma therapy |
-
1998
- 1998-09-04 TR TR2000/00671T patent/TR200000671T2/xx unknown
- 1998-09-04 ID IDW20000639A patent/ID23971A/id unknown
- 1998-09-04 EP EP98944719A patent/EP1012136B1/en not_active Expired - Lifetime
- 1998-09-04 SK SK337-2000A patent/SK3372000A3/sk unknown
- 1998-09-04 AU AU92193/98A patent/AU731153B2/en not_active Expired
- 1998-09-04 CN CN98808990A patent/CN1269786A/zh active Pending
- 1998-09-04 HU HU0100638A patent/HUP0100638A3/hu unknown
- 1998-09-04 WO PCT/US1998/018339 patent/WO1999012895A1/en not_active Application Discontinuation
- 1998-09-04 AT AT98944719T patent/ATE270660T1/de not_active IP Right Cessation
- 1998-09-04 BR BR9811774-2A patent/BR9811774A/pt not_active IP Right Cessation
- 1998-09-04 CA CA002303764A patent/CA2303764C/en not_active Expired - Lifetime
- 1998-09-04 PL PL98339212A patent/PL339212A1/xx unknown
- 1998-09-04 KR KR1020007002515A patent/KR20010023839A/ko not_active Application Discontinuation
- 1998-09-04 ES ES98944719T patent/ES2223141T3/es not_active Expired - Lifetime
- 1998-09-04 IL IL13483998A patent/IL134839A0/xx unknown
- 1998-09-04 JP JP2000510707A patent/JP2001515882A/ja not_active Withdrawn
- 1998-09-04 US US09/148,006 patent/US5977173A/en not_active Expired - Lifetime
- 1998-09-04 NZ NZ503735A patent/NZ503735A/en unknown
- 1998-09-04 DE DE69824966T patent/DE69824966T2/de not_active Expired - Lifetime
- 1998-09-08 PE PE1998000843A patent/PE115499A1/es not_active Application Discontinuation
- 1998-09-08 AR ARP980104479A patent/AR013477A1/es unknown
- 1998-09-09 ZA ZA988230A patent/ZA988230B/xx unknown
- 1998-09-09 CO CO98051818A patent/CO4970731A1/es unknown
-
2000
- 2000-03-06 NO NO20001141A patent/NO20001141L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU9219398A (en) | 1999-03-29 |
| HUP0100638A2 (hu) | 2001-07-30 |
| ES2223141T3 (es) | 2005-02-16 |
| CA2303764A1 (en) | 1999-03-18 |
| PL339212A1 (en) | 2000-12-04 |
| US5977173A (en) | 1999-11-02 |
| SK3372000A3 (en) | 2000-10-09 |
| DE69824966D1 (de) | 2004-08-12 |
| CO4970731A1 (es) | 2000-11-07 |
| DE69824966T2 (de) | 2005-04-07 |
| JP2001515882A (ja) | 2001-09-25 |
| NO20001141L (no) | 2000-05-04 |
| IL134839A0 (en) | 2001-05-20 |
| EP1012136A1 (en) | 2000-06-28 |
| CA2303764C (en) | 2005-02-15 |
| HUP0100638A3 (en) | 2002-12-28 |
| ID23971A (id) | 2000-06-14 |
| AU731153B2 (en) | 2001-03-22 |
| NO20001141D0 (no) | 2000-03-06 |
| BR9811774A (pt) | 2000-08-29 |
| EP1012136B1 (en) | 2004-07-07 |
| ATE270660T1 (de) | 2004-07-15 |
| WO1999012895A1 (en) | 1999-03-18 |
| TR200000671T2 (tr) | 2000-07-21 |
| KR20010023839A (ko) | 2001-03-26 |
| CN1269786A (zh) | 2000-10-11 |
| PE115499A1 (es) | 2000-02-03 |
| ZA988230B (en) | 1999-03-09 |
| NZ503735A (en) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
| CO4970702A1 (es) | Quinolonas antimicrobianas, sus composiciones y sus usos | |
| ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
| SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
| GT199900008A (es) | Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1 | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| ECSP055609A (es) | "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" | |
| GT200100137A (es) | Pro-drogas de derivados de 4-fenil-piridina. | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2194265T3 (es) | Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina. | |
| ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| SV2002000047A (es) | Procedimientos e intermedios para preparar compuestos anticancerosos ref.pc10188 abcz | |
| PA8461301A1 (es) | Agonistas de prostaglandinas | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| PA8465901A1 (es) | Nuevos derivados de la eritromicina | |
| TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| MX9400037A (es) | Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular. | |
| AR001931A1 (es) | Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos | |
| CO5160251A1 (es) | Analogos de prostaglandinas selectivos del receptor fp c16 insaturados | |
| ES2147427T3 (es) | Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| ES2202156T3 (es) | Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. | |
| CR7859A (es) | Sales Fumarato Cristalinas de Furo (2,3-c) Piridinilcarboxamida sustituida con 1-Azabiciclo (2.2.2) octilo y composiciones y preparaciones de las mismas | |
| ES2093782T3 (es) | Piridazindionas y su uso en el tratamiento de trastornos neurologicos. | |
| AR041898A1 (es) | Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales |